Quick Answer
IMMUNIC, INC. reported R&D Expense of $81.98 million for fiscal year 2025.
IMMUNIC, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $81.98M | +2.4% |
| 2024 | $80.05M | -3.8% |
| 2023 | $83.22M | +16.8% |
| 2022 | $71.25M | +16.6% |
| 2021 | $61.12M | +58.2% |
| 2020 | $38.64M | +71.6% |
| 2019 | $22.51M | +134.6% |
| 2018 | $9.60M | -75.6% |
| 2017 | $39.34M | +30.9% |
| 2016 | $30.05M | -24.5% |
| 2015 | $39.77M | +0.7% |
| 2014 | $39.48M | +81.2% |
| 2013 | $21.79M | +327.4% |
| 2012 | $5.10M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $20.01M | -6.4% | -6.4% |
| June 30, 2025 | $21.37M | +16.6% | -0.8% |
| March 31, 2025 | $21.53M | +14.9% | +0.8% |
| September 30, 2024 | $21.37M | +8.0% | +16.6% |
| June 30, 2024 | $18.32M | -13.5% | -2.2% |
| March 31, 2024 | $18.74M | -18.4% | -5.4% |
| September 30, 2023 | $19.80M | +19.7% | -6.5% |
| June 30, 2023 | $21.17M | +28.0% | -7.8% |
- IMMUNIC, INC. showed an increase of +2.4% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2025 period, IMMUNIC, INC.’s r&d expense has grown by 1508.5% (from $5.10 million to $81.98 million).
- The most recent figure is from IMMUNIC, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: